

- Carcinogenesis  
 diet and, 448-449  
 DNA damage and, 430-431  
 molecular basis of multistep, 320-321  
 nonlethal genetic damage in, 280
- Carcinogens  
 direct-acting, 322  
 environmental, 278  
 indirect-acting, 323-324  
 ultimate, 323
- Carcinoid heart disease, 562, 562b, 562f
- Carcinoid tumor, gastric, 773-775, 774b, 774t, 775f
- Carcinoma en cuirasse, 1068
- Carcinoma in situ, 271, 271f  
 of bladder, 964, 965f, 966, 967f  
 of breast  
 ductal, 1057-1058, 1058f, 1059f  
 lobular, 1059-1060, 1059f  
 of penis, 971, 971f
- Carcinomas, 266
- Carcinosarcomas, of endometrium, 1018
- Cardiac atrophy, 533
- Cardiac cirrhosis, in right-sided heart failure, 530
- Cardiac conduction system, 524-525
- Cardiac dilation, 523-524
- Cardiac effects, of noncardiac neoplasms, 576-577, 576t
- Cardiac hypertrophy, 34-35, 523-524, 527, 529f  
 left ventricular, 528f  
 physiologic, 528  
 pressure-overload, 527  
 volume-overload, 527
- Cardiac hypoplasia, 533
- Cardiac myocytes, 524
- Cardiac output, in blood pressure regulation, 488, 488f
- Cardiac stem cells, 525
- Cardiac thrombosis, 126
- Cardiac transplantation, 577, 577f
- Cardiac tumors  
 metastatic, 576-577  
 primary, 575-576, 575f
- Cardiac valves, 524  
 aging effect on, 525
- Cardiogenic shock, due to myocardial infarction, 548
- Cardiomegaly, 523-524
- Cardiomyopathies, 564-573, 564f, 565t, 572b-573b
- Cardiotoxic drugs, myocardial disease due to, 571
- Cardiovascular disease, oral contraceptives in, 421
- Cardiovascular syphilis, 379
- Cardiovascular system, in systemic lupus erythematosus, 222b-225b
- Caries, 727
- Carney complex, cardiac myxomas in, 575
- Carney triad, gastrointestinal stromal tumors in, 775
- Carnitine palmitoyltransferase II deficiency, 1244
- Caroli syndrome, 861
- $\beta$ -carotene, 436, 449
- Carotenoids, 436
- Carotid body tumor, 741-742, 742b, 742f
- Carpal tunnel syndrome, 1234
- Carrier males, of fragile-X syndrome, 169
- Carrier proteins, 9
- Carrier state, in viral hepatitis, 836-837
- Cartilage, developmental disorders of, 1183-1187
- Cartilage-forming tumors, 1200-1203, 1207b  
 chondromas, 1201  
 chondrosarcoma, 1202-1203, 1202b, 1202f  
 osteochondroma, 1200-1203, 1200b, 1200f, 1201f
- Caruncle, urethral, 969
- Caseous necrosis, 43b-44b, 44f
- Caspases, in apoptosis, 53, 302
- Cat-scratch disease, 517
- Catalase, 80  
 in alcohol metabolism, 417-418
- Cataract, due to diabetes mellitus, 1117b-1119b
- Catecholamine cardiomyopathy, 1136
- $\beta$ -catenin gene, 296-297, 297f
- Cathelicidins, in phagocytosis, 81
- Cationic trypsinogen gene, in pancreatitis, 884t
- Caveolae, 9
- Cavernous hemangiomas, 516
- Cavernous lymphangiomas, 517
- Cavernous malformations, of brain, 1271b
- C-C chemokines, 87
- CCR5, in West Nile virus, 356
- CD+ T cell-mediated inflammation, 208-211
- CD4+ helper T cells  
 activation of, 208-209  
 evasion of recognition by, 347  
 in immune responses, 197, 199b-200b  
 in systemic lupus erythematosus, 220-221
- CD4+ T cell-mediated inflammatory reactions, clinical examples of, 210-211
- CD8+ cells, 191, 208
- CD8+ cytotoxic T cell-mediated cell death, 1087
- CD8+ T cell-mediated cytotoxicity, 211
- CD28, in anergy, 213
- CD46, 355
- CDK4, in osteosarcoma, 1199
- CDKN1B (p27/KIP1) gene, in pituitary tumors, 1076t
- CDKN2A gene, 297-298  
 in dysplastic nevi, 1146  
 in melanoma, 1147-1148  
 in pancreatic carcinoma, 893
- Celiac disease  
 HLA alleles and, 215t  
 malabsorption and diarrhea in, 782-783, 782f, 783f, 783b
- Cell  
 basic subcellular constituents of, 7f  
 and extracellular matrix interactions, 24f  
 as a unit of health and disease, 1-29  
 waste disposal of, 13-14
- Cell adhesion molecules (CAMs), 24
- Cell-cell interactions, 10-12, 11f
- Cell cycle, 25-26  
 landmarks, 25f
- Cell damage, sensors of, 72
- Cell death, 15, 33-34  
 enhanced resistance to, 315-316  
 overview of, 38-39  
 via apoptosis, morphologic alterations in, 40t  
 via necrosis  
 clinicopathologic correlations of, 50-52  
 morphologic alterations in, 40, 40t  
 overview of, 39
- Cell-derived mediators, of inflammation, 82-83  
 arachidonic acid metabolites, 83-86  
 cytokines and chemokines, 86-88  
 neuropeptides as, 89-90  
 nitric oxide as, 80
- Cell-derived mediators, of inflammation  
 (*Continued*)  
 platelet-activating factor as, 89  
 vasoactive amines (histamine and serotonin), 83
- $\beta$  cell destruction, mechanism of, in type 1 diabetes mellitus, 1110-1111
- Cell differentiation, vitamin A in, 437
- $\beta$ -cell dysfunction, in diabetes mellitus, 1112
- $\beta$ -cell function, genetic defects in, 1112-1113
- Cell growth  
 metabolism and, in cancer, 301f  
 vitamin A in, 437
- Cell injury, 31-68, 32f, 33f  
 causes of, 39-40  
 chemical (toxic), 51-52  
 clinicopathologic correlations of, 50-52  
 ischemia-reperfusion, 51  
 ischemic and hypoxic, 50-51, 52b  
 mechanisms of, 44-50, 45f, 50b  
 accumulation of oxygen-derived free radicals (oxidative stress) as, 47-49, 48f, 48t  
 damage to DNA and proteins as, 50  
 defects in membrane permeability as, 49-50, 49f  
 depletion of ATP as, 45-46, 45f  
 influx of calcium and loss of calcium homeostasis as, 46-47, 47f  
 mitochondrial damage as, 46, 46f  
 morphologic alterations in, 40-44, 40f, 41f, 40t, 44b  
 irreversible, 42f  
 reversible, 40-41, 42f  
 overview of, 38-39  
 reversible, 38
- Cell lysis, complement system in, 89
- Cell-mediated immunity, 197-198, 197f, 199b-200b  
 in glomerulonephritis, 906
- Cell populations  
 maintaining, 25-29  
 mechanisms regulating, 27f
- Cell proliferation, 25  
 signals and control mechanisms of, 101
- Cell shrinkage, in apoptosis, 53b, 54f
- Cell signaling, 1
- Cell surface glycolipids, as tumor antigens, 312
- Cell surface glycoproteins, as tumor antigens, 312
- Cell-surface receptors, 16
- $\delta$ -cell tumors (somatostatinomas), 1122
- Cell type-specific differentiation antigens, 312
- $\alpha$  cells, of pancreas, 1105
- $\beta$  cells, 1105
- Cellular activation, 15-16
- Cellular adaptations, 31-68  
 of growth and differentiation, 34-38  
 atrophy as, 36-37, 37f  
 hyperplasia as, 35-36  
 hypertrophy as, 33f, 34f, 35f, 34-35  
 metaplasia as, 37-38, 38f  
 to stress, 38b
- Cellular aging, 66-68, 66f, 68b
- Cellular dysfunction, in antibody-mediated hypersensitivity, 205
- Cellular housekeeping, 6-14, 7f
- Cellular metabolism, 14-15  
 altered, in cancer, 282-283
- Cellular proteins, overexpressed or aberrantly expressed, as tumor antigens, 311